Flexion Therapeutics (Flexion Therapeutics) Purchase Of Investment : $-28.6 Mil (TTM As of Sep. 2021)

View and export this data going back to 2014. Start your Free Trial

What is Flexion Therapeutics Purchase Of Investment?

Flexion Therapeutics's purchase of investment for the three months ended in Sep. 2021 was $-3.2 Mil. It means Flexion Therapeutics spent $3.2 Mil on purchasing investments. Flexion Therapeutics's purchase of investment for the trailing twelve months (TTM) ended in Sep. 2021 was $-28.6 Mil.

Compared with last quarter ($0.0 Mil in Jun. 2021 ), Flexion Therapeutics spent more money on purchasing investments in Sep. 2021 ($-3.2 Mil).

Flexion Therapeutics Purchase Of Investment Historical Data

The historical data trend for Flexion Therapeutics's Purchase Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Flexion Therapeutics Purchase Of Investment Chart

Flexion Therapeutics Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Purchase Of Investment

Get a 7-Day Free Trial

-196.06

-356.75

-222.48

-115.47

-79.62

Flexion Therapeutics Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21
Purchase Of Investment	Get a 7-Day Free Trial															-43.73	-23.40	-2.00	-	-3.18

Flexion Therapeutics Purchase Of Investment Calculation

Purchase of Investments represents cash outflow on the purchase of investments in securities.

Purchase Of Investment for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-28.6 Mil.

Flexion Therapeutics Purchase Of Investment Related Terms

Thank you for viewing the detailed overview of Flexion Therapeutics's Purchase Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.

Flexion Therapeutics (Flexion Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Flexion Therapeutics Inc (NAS:FLXN) » Definitions » Purchase Of Investment

Comparable Companies

Traded in Other Exchanges

N/A

Address

10 Mall Road, Suite 301, Burlington, MA, USA, 01803

Website

http://www.flexiontherapeutics.com

Flexion Therapeutics Inc is a United States-based specialty pharmaceutical company. The company focuses on the development and commercialization of novel, local therapies. The company specializes in the treatment of patients with musculoskeletal conditions beginning with osteoarthritis. The products offered by company are zilretta which is used for enhancing the clinical effect of intra-articular corticosteroid treatment.

Executives

Mark S. Levine	officer: General Counsel	1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451
Kerry Wentworth	officer: Chief Regulatory Officer	AGENUS INC., 3 FORBES ROAD, LEXINGTON MA 02421
Christina Willwerth	officer: Chief Strategy Officer	C/O FLEXION THERAPEUTICS, INC. 10 MALL ROAD, SUITE 301 BURLINGTON MA 01803
David Arkowitz	officer: Chief Financial Officer	C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Melissa Layman	officer: Chief Commercial Officer	C/O FLEXION THERAPEUTICS, INC. 10 MALL ROAD, STE. 301 BURLINGTON MA 01803
Scott Kelley	officer: Chief Medical Officer	C/O ASPECT MEDICAL SYSTEMS INC 141 NEEDHAM ST NEWTON MA 02464-1505
Elizabeth Kwo	director	C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Michael D. Clayman	director, officer: President and CEO	C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Alan Milinazzo	director	C/O ORTHOFIX INC, 10115 KINCEY AVENUE STE 250, HUNTERSVILLE NC 28078
Scott A Canute	director	FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
C Ann Merrifield	director
Heath Lukatch	director	326 BOLLAY DRIVE, GOLETA CA 93117
Samuel D Colella	director, 10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Patrick J Mahaffy	director	C/O CLOVIS ONCOLOGY, INC., 5500 FLATIRON PARKWAY, SUITE 100, BOULDER CO 80301
Mark Stejbach	director	C/O TENGION, INC., 2900 POTSHOP LANE, SUITE 100, EAST NORRITON PA 19403